Hartford Investment Management Co. boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,406 shares of the pharmaceutical company’s stock after buying an additional 783 shares during the period. Hartford Investment Management Co.’s holdings in Vertex Pharmaceuticals were worth $5,181,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Mycio Wealth Partners LLC raised its stake in shares of Vertex Pharmaceuticals by 1.5% in the second quarter. Mycio Wealth Partners LLC now owns 1,218 shares of the pharmaceutical company’s stock worth $105,000 after buying an additional 18 shares during the last quarter. Conning Inc. raised its stake in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock worth $494,000 after buying an additional 20 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Vertex Pharmaceuticals by 0.3% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,820 shares of the pharmaceutical company’s stock worth $682,000 after buying an additional 20 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its stake in shares of Vertex Pharmaceuticals by 0.3% in the second quarter. Northwestern Mutual Investment Management Company LLC now owns 9,435 shares of the pharmaceutical company’s stock worth $812,000 after buying an additional 28 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Vertex Pharmaceuticals by 1.1% in the third quarter. Fisher Asset Management LLC now owns 5,168 shares of the pharmaceutical company’s stock worth $451,000 after buying an additional 56 shares during the last quarter. 95.29% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded up 0.42% during mid-day trading on Friday, hitting $82.74. 327,381 shares of the stock traded hands. The stock has a 50 day moving average price of $78.64 and a 200 day moving average price of $87.48. The firm’s market cap is $20.52 billion. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $105.50.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Tuesday, October 25th. The pharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $413.78 million for the quarter, compared to analyst estimates of $423.53 million. Vertex Pharmaceuticals had a negative net margin of 13.45% and a negative return on equity of 5.31%. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) earnings per share. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post $0.83 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of international trademark & copyright legislation. The original version of this article can be viewed at http://www.watchlistnews.com/hartford-investment-management-co-has-5181000-position-in-vertex-pharmaceuticals-incorporated-vrtx/1060013.html.

Several equities analysts have commented on the stock. Leerink Swann set a $112.00 price target on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, September 17th. Janney Montgomery Scott assumed coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 17th. They issued a “neutral” rating and a $98.00 price target for the company. Jefferies Group restated a “buy” rating and issued a $107.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, September 15th. BMO Capital Markets restated a “hold” rating and issued a $87.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, September 15th. Finally, Stifel Nicolaus boosted their price target on shares of Vertex Pharmaceuticals from $105.00 to $109.00 and gave the stock a “buy” rating in a research note on Thursday, September 15th. Sixteen research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $105.91.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 6,500 shares of the business’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $77.13, for a total transaction of $501,345.00. Following the sale, the director now directly owns 274,725 shares in the company, valued at approximately $21,189,539.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Stuart A. Arbuckle sold 1,208 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $90.00, for a total transaction of $108,720.00. Following the sale, the executive vice president now owns 113,358 shares in the company, valued at $10,202,220. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.